News

The company has previously submitted a 510(k) pre-market notification application to the FDA. Upon its review, the FDA determined that the device was exempt from the agency’s pre-market

Under the terms of the agreement, RxElite will be responsible for the exclusive US supply of active pharmaceutical ingredient to be used in the manufacture of the generic

Roxane Laboratories’s Morphine sulfate CII is available in 15mg, 30mg tablet strengths and 10mg/5ml, 20mg/5ml oral solution strengths. Roxane Laboratories’s Morphine sulfate tablets and oral solutions CII are

The purpose of the study will be to demonstrate safety and monitor viral load changes in patients who are not yet eligible for antiviral drug therapy. Energex Systems’s

This randomized, double-blind, placebo-controlled Phase III trial is designed to evaluate the efficacy and safety of MAP0004 in treating acute migraine. The primary efficacy endpoints will be pain

Lumedx’s CardioPACS 5.0 is said to be a next generation PACS solution that offers new and better ways to manage images and data with a fully integrated suite

NovaBone, a calcium-phosphate silicate, is said to be the only synthetic that is osteostimulative, directly increasing the proliferation and activity of osteoblasts, the cells responsible for new bone

Most of the money was spent on fees, travel expenses, and other direct payments to Vermont physicians, hospitals, universities and others for the purpose of marketing their products.

The patent at issue was granted to Angiotech Pharmaceuticals by the European Patent Office on June 25, 1997. However, five different companies opposed the patent and the UK